New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) e...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID-19 vaccination: blood clotting information for healthcare professionals, PHE ( updated 23rd August 2021)
Information for healthcare professionals on blood clotting following COVID-19 vaccination. 23 August 2021Updated guidance document. 8 June 2021Updated to include: antiphospholipid syndrome, interchangeability of COVID-19 vaccines, samples required for whole genome sequencing and the latest MHRA data. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 23, 2021 Category: Consumer Health News Source Type: news

A 28-Year-Old With Antiphospholipid Syndrome A 28-Year-Old With Antiphospholipid Syndrome
This week's question involves antiphospholipid syndrome.Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 9, 2021 Category: Consumer Health News Tags: Med Students Interactive Quiz Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with co...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID-19 vaccination: blood clotting information for healthcare professionals, PHE (updated 8th June 2021)
This guidance has been updated to include antiphospholipid syndrome, interchangeability of COVID-19 vaccines, samples required for whole genome sequencing and the latest MHRA data. 8 June 2021Updated to include: antiphospholipid syndrome, interchangeability of COVID-19 vaccines, samples required for whole genome sequencing and the latest MHRA data. 7 May 2021Updated information for healthcare professionals on blood clotting following COVID-19 vaccination. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 9, 2021 Category: Consumer Health News Source Type: news

COVID-19 vaccination: blood clotting information for healthcare professionals, PHE (updated 8th June 2021)
Information for healthcare professionals on blood clotting following COVID-19 vaccination. 8 June 2021Updated to include: antiphospholipid syndrome, interchangeability of COVID-19 vaccines, samples required for whole genome sequencing and the latest MHRA data. 7 May 2021Updated information for healthcare professionals on blood clotting following COVID-19 vaccination. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 8, 2021 Category: Consumer Health News Source Type: news

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

JOHN STAPLETON on the 'cure' that killed his wife Lynn Faulds Wood
JOHN STAPLETON: Lynn Faults Wood suffered a stroke caused by a disease of which few people have heard. A disease with the hard-to-remember name of antiphospholipid syndrome (Source: the Mail online | Health)
Source: the Mail online | Health - April 20, 2021 Category: Consumer Health News Source Type: news

Managing Diffuse Peripheral Ischemia in Antiphospholipid Syndrome Managing Diffuse Peripheral Ischemia in Antiphospholipid Syndrome
A complex case of refractory peripheral ischemia in a 39-year-old man with APS and type 1 diabetes.HSS Grand Rounds Complex Cases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 14, 2021 Category: Consumer Health News Tags: Rheumatology Clinical Case Source Type: news

Lipid presentation by the protein C receptor links coagulation with autoimmunity
Antiphospholipid antibodies (aPLs) cause severe autoimmune disease characterized by vascular pathologies and pregnancy complications. Here, we identify endosomal lysobisphosphatidic acid (LBPA) presented by the CD1d-like endothelial protein C receptor (EPCR) as a pathogenic cell surface antigen recognized by aPLs for induction of thrombosis and endosomal inflammatory signaling. The engagement of aPLs with EPCR-LBPA expressed on innate immune cells sustains interferon- and toll-like receptor 7–dependent B1a cell expansion and autoantibody production. Specific pharmacological interruption of EPCR-LBPA signaling attenua...
Source: ScienceNOW - March 11, 2021 Category: Science Authors: Müller-Calleja, N., Hollerbach, A., Royce, J., Ritter, S., Pedrosa, D., Madhusudhan, T., Teifel, S., Meineck, M., Häuser, F., Canisius, A., Nguyen, T. S., Braun, J., Bruns, K., Etzold, A., Zechner, U., Strand, S., Radsak, M., Strand, D., G Tags: Immunology, Medicine, Diseases, Online Only r-articles Source Type: news

New research finds ginger counters certain autoimmune diseases in mice
(Michigan Medicine - University of Michigan) The main bioactive compound of ginger root lowers autoantibody production and helps halt disease progression in mice with antiphospholipid syndrome and lupus. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 6, 2021 Category: Biology Source Type: news

Developing new classification criteria for improving antiphospholipid syndrome research
(Hospital for Special Surgery) An international team of more than 80 collaborators led by Hospital for Special Surgery (HSS) investigators is developing new classification criteria for clinical research of antiphospholipid syndrome (APS), a life-threatening autoimmune clotting disorder. In a paper published online in Arthritis Care& Research, the investigators reported on the first two of four phases of criteria development. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2020 Category: International Medicine & Public Health Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need f...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Scientists Have Uncovered the Likely Cause of a Serious COVID-19 Symptom: Blood Clotting
One of the more surprising symptoms of COVID-19 has been the blood clots that many patients, including younger ones, have experienced with the infection. The clots have in some cases led to dangerous blockages in the lungs, caused strokes and even death, even in people without a history of circulatory conditions. In a paper published in Science earlier this week, researchers provide a glimpse into what may be driving the clots triggered by COVID-19 infection. The group found that a specific set of antibodies known as autoantibodies—which are rogue versions of cells meant to defend the body from pathogens, but instead...
Source: TIME: Health - November 5, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

New Target to Combat COVID-Related Thrombosis? New Target to Combat COVID-Related Thrombosis?
More than half of patients hospitalized with COVID-19 have prothrombotic antiphospholipid autoantibodies in their blood, which may trigger to blood clots, new research suggests.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 4, 2020 Category: Intensive Care Tags: Cardiology News Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revasculariz...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

'Hypercoagulation,' Antiphospholipid Antibodies Seen in COVID-19
Marked coagulopathy and presence of antiphospholipid antibodies and cerebral infarcts in patients with COVID-19 suggest the infection represents a 'hypercoagulable' state, experts write. (Source: WebMD Health)
Source: WebMD Health - April 15, 2020 Category: Consumer Health News Source Type: news

' Hypercoagulation,' Antiphospholipid Antibodies Seen in COVID-19'Hypercoagulation,' Antiphospholipid Antibodies Seen in COVID-19
Marked coagulopathy and presence of antiphospholipid antibodies and cerebral infarcts in patients with COVID-19 suggest the infection represents a'hypercoagulable'state, experts write.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 14, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefi...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Rivaroxaban Misfires in Antiphospholipid Syndrome Rivaroxaban Misfires in Antiphospholipid Syndrome
Rivaroxaban not only failed to show noninferiority to warfarin, but trended toward higher thrombosis risk in patients with APS.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 17, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Study Compares Anticoagulants for Antiphospholipid Syndrome
TUESDAY, Oct. 15, 2019 -- In thrombotic antiphospholipid antibody syndrome (APS), rivaroxaban is not noninferior to dose-adjusted vitamin K antagonists (VKAs), according to a study published online Oct. 15 in the Annals of Internal Medicine. Josep... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 15, 2019 Category: Pharmaceuticals Source Type: news

DAPT for Preventing Thrombosis in Antiphospholipid Syndrome DAPT for Preventing Thrombosis in Antiphospholipid Syndrome
Can dual antiplatelet therapy effectively prevent thrombosis recurrence in patients with antiphospholipid syndrome? How does it compare to warfarin?Rheumatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 4, 2019 Category: Allergy & Immunology Tags: Rheumatology Journal Article Source Type: news

How common gut bacteria trigger a lethal autoimmune disease
Antiphospholipid syndrome, an immune system disorder that raises the risk of blood clots, may be triggered by the common gut bactrium Roseburia intestinalis. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 18, 2019 Category: Universities & Medical Training Source Type: news

A probable case of catastrophic antiphospholipid syndrome: Should high-dose steroids be given in the setting of polymicrobial sepsis?
In this clinical vignette, we present a case of a 59-year-old woman with catastrophic antiphospholipid syndrome likely triggered by polymicrobial sepsis. The diagnostic criteria and clinical manifestations of catastrophic antiphospholipid syndrome are reviewed. We also compare diagnostic criteria and clinical manifestations with other clinical entities in the differential diagnosis, including thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome, disseminated intravascular coagulation, sepsis, and inflammatory bowel disease. Catastrophic antiphospholipid syndrome is a rare, but lethal condition, and treatment recom...
Source: Current Awareness Service for Health (CASH) - May 29, 2019 Category: Consumer Health News Source Type: news

Impeding white blood cells in antiphospholipid syndrome reduced blood clots
(Michigan Medicine - University of Michigan) A new study examined APS at the cellular level and found that two drugs reduced development of blood clots in mice affected with the condition. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 25, 2019 Category: International Medicine & Public Health Source Type: news

Antiphospholipid Syndrome: Insights Into a Rare Autoimmune Disease Antiphospholipid Syndrome: Insights Into a Rare Autoimmune Disease
A conversation with Dr Doruk Erkan about the proper diagnosis and management of this life-threatening clotting disease.Hospital for Special Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 29, 2019 Category: Consumer Health News Tags: Rheumatology Expert Interview Source Type: news

Presence of Antiphospholipid Antibodies Tied to First-Time MI
FRIDAY, Nov. 30, 2018 -- There is a strong and independent association between the presence of antiphospholipid antibodies (aPLs) and first-time myocardial infarction (MI), according to a research letter published recently in the Annals of Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 30, 2018 Category: Pharmaceuticals Source Type: news

Pregnancy and APS: Results Look Encouraging (CME/CE)
(MedPage Today) -- Intrauterine fetal death was the first sign in most women with antiphospholipid syndrome (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - November 7, 2018 Category: Rheumatology Source Type: news

Antiphospholipid Antibody Linked to First MI Antiphospholipid Antibody Linked to First MI
The case-control PAROKRANK study identified a strong association between an anticardiolipin antibody and MI, but also raises a host of new questions about the relationship.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 23, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Antibodies Common in Autoimmune Disorders Could Be MI Risk Factor
(MedPage Today) -- Antiphospholipid antibodies out-predicted conventional factors (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - October 23, 2018 Category: Rheumatology Source Type: news

Antibodies linked to heart attacks
(Karolinska Institutet) Levels of antiphospholipid antibodies, which are associated with rheumatic diseases, are also elevated in myocardial infarction without any autoimmune co-morbidity, a study from Karolinska Institutet in Sweden published in The Annals of Internal Medicine reports. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2018 Category: International Medicine & Public Health Source Type: news

Across the Table on Antiphospholipid Syndrome
(MedPage Today) -- Jack Cush, MD, and Doruk Erkan, MD, MPH, discuss this sometimes frustrating condition (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 31, 2017 Category: American Health Source Type: news

Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis
Blood coagulation functions as part of the innate immune system by preventing bacterial invasion, and it is critical to stopping blood loss (hemostasis). Coagulation involves the external membrane surface of activated platelets and leukocytes. Using lipidomic, genetic, biochemical, and mathematical modeling approaches, we found that enzymatically oxidized phospholipids (eoxPLs) generated by the activity of leukocyte or platelet lipoxygenases (LOXs) were required for normal hemostasis and promoted coagulation factor activities in a Ca2+- and phosphatidylserine (PS)–dependent manner. In wild-type mice, hydroxyeicosatet...
Source: Signal Transduction Knowledge Environment - November 28, 2017 Category: Science Authors: Lauder, S. N., Allen-Redpath, K., Slatter, D. A., Aldrovandi, M., OConnor, A., Farewell, D., Percy, C. L., Molhoek, J. E., Rannikko, S., Tyrrell, V. J., Ferla, S., Milne, G. L., Poole, A. W., Thomas, C. P., Obaji, S., Taylor, P. R., Jones, S. A., de Groot Tags: STKE Research Articles Source Type: news

Heartbroken woman, 23, who lost five babies in six years
Shannon Reed, 23, from Prudhoe, near Newcastle, has been diagnosed with 'sticky blood syndrome', or antiphospholipid syndrome - after years of mystery surrounding her miscarriages. (Source: the Mail online | Health)
Source: the Mail online | Health - November 8, 2017 Category: Consumer Health News Source Type: news

Antiphospholipid syndrome: diagnosis and management
Dr Anisur Rahman and Dr Salma Ahmed discuss the diagnosis and management of antiphospholipid syndrome (APS). (Source: GP Online Education)
Source: GP Online Education - September 13, 2017 Category: Primary Care Tags: Autoimmune disorders Source Type: news

Heparin, ASA Aids Live Birth With Antiphospholipid Antibody Heparin, ASA Aids Live Birth With Antiphospholipid Antibody
Unfractionated heparin added to aspirin is superior to aspirin alone in promoting live births among women with antiphospholipid syndrome and recurrent pregnancy loss, a meta-analysis shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Prevalence of Antiphospholipid Syndrome Up for Roma SLE
Roma systemic lupus erythematosus patients also have significantly higher prevalence of abortions (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 14, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Rheumatology, Journal, Source Type: news

Antiphospholipid Syndrome: Role of Vascular Endothelial Cells Antiphospholipid Syndrome: Role of Vascular Endothelial Cells
This review explores the role of vascular endothelial cell dysfunction in antiphospholipid syndrome, an autoimmune prothrombotic condition. Might this pathway provide a viable target for therapy?Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Gut bacteria may be a trigger for antiphospholipid syndrome
The gut microbiomes of patients with antiphospholipid syndrome show higher levels of phospholipid-producing bacteria, and this findings point to microbes being a trigger for this life-threatening disease, according to new research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 13, 2016 Category: Science Source Type: news

Gut bacteria may be a trigger for antiphospholipid syndrome
(American College of Rheumatology) The gut microbiomes of patients with antiphospholipid syndrome show higher levels of phospholipid-producing bacteria, and this findings point to microbes being a trigger for this life-threatening disease, according to new research findings presented this week at the American College of Rheumatology Annual Scientific Meeting in Washington. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - November 12, 2016 Category: Global & Universal Source Type: news

Rivaroxaban 'could be a safe treatment option for antiphospholipid syndrome'
The drug rivaroxaban could be an effective means of treating some patients with thromboticantiphospholipid syndrome, according to a new study. Led by University College London and funded byArthritis Research UK, the research has suggested that the drug - which works by inhibiting the formation of blood clots - could be a useful tool in the treatment of those with this serious condition, which affects approximately 15 per cent of patients withlupus and may also occur on its own. The danger of antiphospholipid syndrome Thrombotic antiphospholipid syndrome is classified as a rare condition, but is probably underdiagnosed. It ...
Source: Arthritis Research UK - August 29, 2016 Category: Rheumatology Source Type: news

Antiphospholipid Syndrome
Title: Antiphospholipid SyndromeCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/29/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - August 29, 2016 Category: Rheumatology Source Type: news

Pravastatin Shows Promise in Pregnant Women With Antiphospholipid Syndrome Pravastatin Shows Promise in Pregnant Women With Antiphospholipid Syndrome
Pravastatin may improve pregnancy outcomes in women with antiphospholipid syndrome (APS) refractory to standard antithrombotic therapy, a new study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 1, 2016 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

I Never Thought Stroke Would Happen to Me
by Myra Wilson, Stroke Survivor On November 3, 2014, I was in nursing school working as a student nurse at a hospital in Seattle. My first sign that something was not quite right was when I was walking through the nursing station and both of my eyes went blurry. I could still see color but I couldn't see letters. It was blurry for about 30 seconds before clearing up again. I was going to lunch and went to give a report to another nurse. The nurse noticed while I was speaking that I slurred my speech. I didn't notice my speech was slurred at all. It was at that time that I experienced a sudden sharp pain on the right s...
Source: Healthy Living - The Huffington Post - May 13, 2016 Category: Consumer Health News Source Type: news

Can Infections Trigger Autoimmunity? (CME/CE)
(MedPage Today) -- Case reports suggest a post-infectious association with antiphospholipid syndrome (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - May 10, 2016 Category: Consumer Health News Source Type: news

Newer Anticoagulants Helpful in Antiphospholipid Syndrome (CME/CE)
(MedPage Today) -- But lack of reversal agents for some complicates the picture (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 12, 2016 Category: Cardiology Source Type: news

Osmosis Question of the Week Feb 5, 2016Osmosis Question of the Week Feb 5, 2016
This week's question involves antiphospholipid syndrome. Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 5, 2016 Category: Consumer Health News Tags: Med Students Interactive Quiz Source Type: news

Antibody Signals Adverse Pregnancy Outcome (CME/CE)
(MedPage Today) -- Lupus anticoagulant was the only antiphospholipid antibody linked with poor birth outcome (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - January 22, 2016 Category: OBGYN Source Type: news